Story thread · 2 reports / 2 sources
Barclays cuts Cellectis stock rating on gene editing concerns
investing.com · 3h
First report: Cellectis quits CAR-Ts and pivots to ‘in vivo’ gene editing — biopharmadive.com, 1d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.